Use of apolipoprotein parameters and endpoints in drug development and approval processes

American Journal of Cardiology

Volumn 81, Issue 8 A, 1998, Pages 40F-47F

  Alaupovic, Petar ^a   Dujovne, Carlos A ^b  

^a OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

^b Kansas Foundation for Clinical Pharmacology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN; APOLIPOPROTEIN A1; APOLIPOPROTEIN A2; APOLIPOPROTEIN B; APOLIPOPROTEIN C; APOLIPOPROTEIN E; LIPOPROTEIN;

ATHEROSCLEROSIS; CONFERENCE PAPER; DRUG APPROVAL; LIPOPROTEIN BLOOD LEVEL; PRIORITY JOURNAL; TURBIDIMETRY;

EID: 0344589403     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(98)00260-4     Document Type: Conference Paper

References (113)

1. Alaupovic P. The significance of apolipoproteins for structure, function and classification of plasma lipoproteins. In: Bradley WA, Gianturco SH, Segrest JP, eds. Methods in Enzymology. Plasma Lipoproteins, Part C, Quantitation, San Diego: Academic Press, 1996:32-60.
2. Francheschini G. Apolipoprotein function in health and disease: insights from natural mutations. Eur J Clin Invest 1996;26:733-746.
3. Patsch W, Gotto AM Jr. Apolipoproteins: pathophysiology and clinical implications. In: Bradley WA, Gianturco SH, Segrest JP, eds. Methods in Enzymology Plasma Lipoproteins. Part C, Quantitation, San Diego: Academic Press, 1996: 3-32.
4. Alaupovic P, McConathy WJ, Fesmire J, Tavella M, Bard JM. Profiles of apolipoproteins and apolipoprotein B-containing lipoprotein particles in dyslipoproteinemias. Clin Chem 1988;34:B13-B27.
5. Bachorik PS, Kwiterovich PO Jr. Apolipoprotein measurements in clinical biochemistry and their utility vis-a-vis conventional assays. Clin Chim Acta 1988;178:1-34.
6. Albers JJ, Brunzell JD, Knopp RH. Apoprotein measurements and their clinical application. Clin Lab Med 1989;9:137-152.
7. Report of the National Cholesterol Education Program Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults. Arch Intern Med 1988;148:36-39.
8. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel II). JAMA 1993;268:3015-3023.
9. Albers JJ, Wahl PW, Cabana VG, Hazzard WR, Hoover JJ. Quantification of apolipoprotein A-I of human plasma high density lipoprotein. Metabolism 1976; 25:633-644.
10. Reman FC, Vermond A. The quantitative determination of apolipoprotein A-I (apo-lp-Gln I) in human serum by radial immunodiffusion assay (RID). Clin Chim Acta 1978;87:387-394.
11. 1 and apoB in humans according to age and sex. Clin Chim Acta 1979;95: 311-315.
12. Dedonder-Decoopman E, Fievet-Desreumaux C, Campos E, Moulin S, Dewailly P, Sezille G, Jaillard J. Plasma levels of VLDL- + LDL-cholesterol, HDL-cholesterol, triglycerides and apoproteins B and A-I in a healthy population. Influence of several risk factors. Atherosclerosis 1980; 37:559-568.
13. Donahue RP, Jacobs DR Jr, Sidney S, Wagenknecht LE, Albers JJ, Hulley SB. Distribution of lipoproteins and apolipoproteins in young adults - The Cardia Study. Arteriosclerosis 1989;9:656-664.
14. Kesteloot H, Oviasu VO, Obasohan AO, Olomu A, Cobbaert C, Lissens W. Serum lipid and apolipoprotein levels in a Nigerian population sample. Atherosclerosis 1989;78:33-38.
15. Ma X, Wearne K, Lynch WJ, Masarei JR. Apolipoprotein A-I and A-II levels in an Australian population. Pathology 1989;21:42-45.
16. Capurso A, Di Tammaso M, Mogavero AM, Resta F, Palmisano S, Ciancia D, Taverniti R, Angelini G. Apolipoprotein profile of a sample of Italian population. Correlations with coronary risk factors. In: Descovich GC, Gaddi A, Magri GL, Lenzi S, eds. Atherosclerosis and Cardiovascular Disease. 7th International Meeting, Lancaster: Kluwer Academic Publishers, 1990:529-534.
17. Noma A, Hata Y, Goto Y. Quantitation of serum apolipoprotein A-I, A-II, B, C-II, C-III and E in healthy Japanese by turbidimetric immunoassay: reference values and age-and sex-related differences. Clin Chim Acta 1991;199:147-158.
18. Jungner I, Walldius G, Holme I, Kolar W, Steiner E. Apolipoprotein-B and A-I in relation to serum cholesterol and triglycerides in 43,000 Swedish males and females. Int J Clin Lab Res 1992;21:247-255.
19. Lyu L-C, Shieh M-J, Ordovas JM, Lichtenstein AH, Wilson PWF, Schaefer EJ. Plasma lipoprotein and apolipoprotein levels in Taipei and Framingham. Arterioscler Thromb 1993;13:1429-1440.
20. Lintott CJ, Hanger HC, Scott RS, Sainsbury R, Frampton C. Lipid, lipoprotein and apolipoprotein distributions in an elderly New Zealand population. Aust NZ J Med 1993;23:162-167.
21. Brown SA, Hutchinson R, Morrisett J, Boerwinkle E, Davis CE, Gotto AMJ, Patsch W, for the ARIC Study Group. Plasma lipid, lipoprotein cholesterol, and apoprotein distributions in selected US communities. The Atherosclerosis Risk in Communities (ARIC) Study. Arterioscler Thromb 1993; 13:1139-1158.
22. Fong P-C, Tam SC-F, Tai Y-T, Lau C-P, Lee J, Sha Y-Y. Serum lipid and apolipoprotein distributions in Hong Kong Chinese. J Epidemiol Community Health 1994;48:355-359.
23. Porkka KVK, Viikari JSA, Rønnemaa T, Marniemi J, Åkerblom HK. Age and gender specific serum lipid and apolipoprotein fractiles of Finnish children and young adults. The Cardiovascular Risk in Young Finns Study. Acta Paediatr 1994;83:838-848.
24. Avogaro P, Bittolo Bon G, Cazzolato G, Rorai E. Relationship between apo lipoproteins and chemical components of lipoproteins in survivors of myocardial infarction. Atherosclerosis 1980;37:69-76.
25. DeBacker G, Rosseneu M, Deslypere JP. Discriminative value of lipids and apoproteins in coronary heart disease. Atherosclerosis 1982;42:197-203.
26. Maciejko JJ, Holmes DR, Kottke BA, Zinsmeister AR, Dinh DM, Mao SJT. Apolipoprotein A-I as a marker of angiographically assessed coronary-artery disease. N Engl J Med 1983;309:385-389.
27. Noma A, Yokosuka T, Kitamura K. Plasma lipids and apolipoproteins as discriminators for presence and severity of angiographically defined coronary artery disease. Atherosclerosis 1983;49:1-7.
28. Bittolo Bon G, Cazzolato G, Saccardi M, Kostner GM, Avogaro P. Total plasma apoE and high density lipoprotein apoE in survivors of myocardial infarction. Atherosclerosis 1984;53:69-75.
29. Kukita H, Hiwada K, Kokubu T. Serum apolipoproteins A-I, A-II and B levels and their discriminative values in relatives of patients with coronary artery disease. Atherosclerosis 1984;51:261-267.
30. Kukita H, Hamada M, Hiwada K, Kokubu T. Clinical significance of measurements of serum apolipoprotein A-I, A-II and B in hypertriglyceridemic male patients with and without coronary artery disease. Atherosclerosis 1985;55: 143-149.
31. Kottke BA, Zinsmeister AR, Holmes DR Jr, Kneller RW, Hallaway BJ, Mao SJT. Apolipoproteins and coronary artery disease. Mayo Clin Proc 1986;61:313-320.
32. Durrington PN, Hunt L, Ishola M, Kane J, Stephens WP. Serum apolipoproteins AI and B and lipoproteins in middle aged men with and without previous myocardial infarction. Br Heart J 1986;56:206-212.
33. Lehtonen A, Marniemi J, Inberg M, Maatela J, Alanen E, Niittymaki K. Levels of serum lipids, apolipoproteins A-I and B and pseudocholinesterase activity and their discriminative values in patients with coronary by-pass operation. Atherosclerosis 1986;59:215-221.
34. Sedlis SP, Schechtman KB, Ludbrook PA, Sobel BE, Schonfeld G. Plasma apoproteins and the severity of coronary artery disease. Circulation 1986;73: 978-986.
35. Aro A, Soimakallio S, Voutilainen E, Ehnholm C, Wiljasalo M. Serum lipoprotein lipid and apoprotein levels as indicators of the severity of angiographically assessed coronary artery disease. Atherosclerosis 1986;62:219-225.
36. Hamsten A, Walldius G, Szamos A, Dahlen G, de Faire U. Relationship of angiographically defined coronary artery disease to serum lipoproteins and apolipoproteins in young survivors of myocardial infarction. Circulation 1986;73: 1097-1110.
37. Durrington PN, Ishola M, Hunt L, Arrol S, Bhatnagar D. Apolipoproteins(a), AI, and B and parental history in men with early onset ischaemic heart disease. Lancet 1988;1:1070-1073.
38. Tasaki H, Nakashima Y, Nandate H, Yashiro A, Kawashima T, Kuroiwa A. Comparison of serum lipid values in variant angina pectoris and fixed coronary artery disease with normal subjects. Am J Cardiol 1989;63:1441-1445.
39. Reinhart RA, Gani K, Arndt MR, Broste SK. Apolipoproteins A-I and B as predictors of angiographically defined coronary artery disease. Arch Intern Med 1990;150:1629-1633.
40. Schwartzkopff W, Schleicher J, Pottins I, Yu S-B, Han C-Z, Du D-Y. Lipids, lipoproteins, apolipoproteins, and other risk factors in Chinese men and women with and without myocardial infarction. Atherosclerosis 1990;82:253-259.
41. Tybjaerg-Hansen A, Nordestgaard BG, Gerdes LU, Humphries SE. Variation of apo lipoprotein B gene is associated with myocardial infarction and lipoprotein levels in Danes. Atherosclerosis 1991;89:69-81.
42. Pollak H, Arnoldner O, Enenkel W, Fischer M, Trubert-Exinger D. Apolipoprotein A and prognosis after myocardial infarction in non-diabetic men. Klin Wochenschr 1991;69:10-15.
43. Kwiterovich PO, Coresh J, Smith HH, Bachorik PS, Derby CA, Pearson TA. Comparison of the plasma levels of apo lipoprotein B and A-1, and other risk factors in men and women with premature coronary artery disease. Am J Cardiol 1992;69:1015-1021.
44. Genest JJ Jr, Martin-Munley SS, McNamara JR, Ordovas JM, Jenner J, Myers RH, Silberman SR, Wilson PWF, Salem DN, Schaefer EJ. Familial lipoprotein disorders in patients with premature coronary artery disease. Circulation 1992; 85:2025-2033.
45. 3 cholesterol, apo A-I and apo A-II, and increased risk of myocardial infarction. Circulation 1992;85:22-29.
46. Sigurdsson G, Baldursdottir A, Sigvaldason H, Agnarsson U, Thorgeirsson G, Sigfusson N. Predictive value of apo lipoproteins in a prospective survey of coronary artery disease in men. Am J Cardiol 1992;69:1251-1254.
47. Nieminen M S, Mattila KJ, Aalto-Setälå K, Kuusi T, Kontula K, Kauppinen-Mäkelin R, Ehnholm C, Jauhiainen M, Valle M, Taskinen M-R. Lipoproteins and their genetic variation in subjects with and without angiographically verified coronary artery disease. Arterioscler Thromb 1992;12:58-69.
48. Wald NJ, Law M, Watt HC, Wu TS, Bailey A, Johnson AM, Craig WY, Ledue TB, Haddow JE. Apo lipoproteins and ischaemic heart disease: implications for screening. Lancet 1994;343:75-79.
49. Fujiwara R, Kutsumi Y, Hayashi T, Nishio H, Koshino Y, Shimada Y, Nakai T, Miyabo S. Relation of angiographically defined coronary artery disease and plasma concentrations of insulin, lipid, and apolipoprotein in normolipidemic subjects with varying degrees of glucose tolerance. Am J Cardiol 1995;75:122-126.
50. Wentworth MA, O'Brien T, Rastogi A, Kottke BA. Apolipoprotein A-II levels and coronary artery disease in subjects with and without diabetes - a study with use of a specific radioimmunoassay for apolipoprotein A-II. Mayo Clin Proc 1993;68:556-560.
51. Blankenhorn DH, Alaupovic P, Wickham E, Chin HP, Azen SP. Prediction of angiographic change in native human coronary arteries and aortocoronary bypass grafts - lipid and nonlipid factors. Circulation 1990;81:470-476.
52. Blankenhorn DH, Azen SP, Kramsch DM, Mack WJ, Cashin-Hemphill L, Hodis HN, DeBoer LWV, Mahrer PR, Masteller MJ, Vailas LI, Alaupovic P, Hirsch LJ, and the MARS Research Group. Coronary angiographic changes with lovastatin therapy. The Monitored Atherosclerosis Regression Study (MARS). Ann Intern Med 1993;119:969-976.
53. Alaupovic P, Hodis HN, Knight-Gibson C, Mack WJ, LaBree L, Cashin-Hemphill L, Corder CN, Kramsch DM, Blankenhorn DH. Effects of lovastatin on apoA-and apoB-containing lipoprotein families in a subpopulation of patients participating in the Monitored Atherosclerosis Regression Study (MARS). Arterioscler Thromb 1994;14:1906-1914.
54. MAAS Investigators. Effect of simvastatin on coronary atheroma: the Multicenter Anti-Atheroma Study (MAAS). Lancet 1994;344:633-638.
55. Whayne TF, Alaupovic P, Curry MD, Lee ET, Anderson PS, Schechter E. Plasma apolipoprotein B and VLDL-, LDL-, and HDL-cholesterol as risk factors in the development of coronary artery disease in male patients examined by angiography. Atherosclerosis 1981;39:411-424.
56. Gimpel JA, van Rijn HJM, Kortlandt W. Lipoproteins, lipids and apolipoproteins as risk factors for angiographically assessed coronary artery disease. Clin Chem Enzym Comms 1992;5:63-68.
57. Kwiterovich PO, Coresh J, Bachorik PS. Prevalence of hyperapobetalipoproteinemia and other lipoprotein phenotypes in men (aged <50 years) and women (<60 years) with coronary artery disease. Am J Cardiol 1993;71:631-639.
58. Tornvall P, Båvenholm P, Landou C, de Faire U, Hamsten A. Relation of plasma levels and composition of apolipoprotein B-containing lipoproteins to angiographically defined coronary artery disease in young patients with myocardial infarction. Circulation 1993;88:2180-2189.
59. Hobbs GA, Wagner SG, Levinson SS. Relationships between triglycerides, lipoproteins, glucose and coronary artery disease. Clin Chim Acta 1995;238:59-70.
60. Lamarche B, Després J-P, Moorjani S, Cantin B, Dagenais GR, Lupien P-J. Prevalence of dyslipidemic phenotypes in ischemic heart disease (prospective results from the Quebec Cardiovascular Study). Am J Cardiol 1995;75:1189-1195.
61. Curry MD, Alaupovic P, Suenram CA. Determination of apolipoprotein A and its constitutive A-I and A-II polypeptides by separate electroimmunoassays. Clin Chem 1976;22:315-322.
62. Schonfeld G, Chen J-S, McDonnell WF, Jeng I. Apolipoprotein A-II content of human plasma high density lipoproteins measured by radioimmunoassay. J Lipid Res 1977;18:645-655.
63. Cheung MC, Albers JJ. The measurement of apolipoprotein A-I and A-II levels in men and women by immunoassay. J Clin Invest 1977;60:43-50.
64. Riesen WF, Mordasini RC, Middelhoff GW. Quantitation of the two major apoproteins of human high density lipoproteins by solid phase radio immuno assay. FEBS Lett 1978;91:35-39.
65. Sistonen P, Ehnholm C. On the heritability of serum high density lipoproteins in twins. Am J Hum Genet 1980;32:1-7.
66. Goldberg RB, Karlin JB, Juhn DJ, Scanu AM, Edelstein C, Rubenstein AH. Characterization and measurement of human apolipoprotein A-II by radioimmunoassay. J Lipid Res 1980;21:902-912.
67. Musliner TA, Garner PA, Henderson LO, Herbert PN. Radioimmunoassay of apolipoprotein A-II. Arteriosclerosis 1982;2:160-169.
68. Nomata Y, Matsukawa A, Hiraoka K, Sakurabayashi I, Iimura Y, Kawai T. Purification and properties of apolipoprotein A-I and A-II from human serum high density lipoprotein (HDL). In: Hiraii H, ed. Electrophoresis '83, Berlin: Walter de Gruyter & Co., 1984:695-702.
69. Rosseneu M, Vinaimont N, Musliner TA, Bernier D, Herbert PN, Belpaire F. Immunonephelometry of apolipoprotein A-II in plasma. Clin Chem 1984;30: 234-237.
70. Schriewer H, Emke F, Assman G. Turbidimetric assay of apolipoprotein A-II. J Clin Chem Clin Biochem 1985;23:355-359.
71. Stein EA, DiPersio L, Pesce AJ, Kashyap M, Kao J-T, Srivastava L, McNerney C. Enzyme-linked immunoabsorbant assay of apolipoprotein AII in plasma with use of a monoclonal antibody. Clin Chem 1986;32:967-971.
72. Puchois P, Kandoussi A, Duriez P, Fruchart JC, McConathy WJ, Koren E. Quantitative determination of human plasma apolipoprotein A-II by a non competitive enzyme-linked immunosorbent assay. J Immunoassay 1986;7:285-307.
73. Schonfeld G, George PK, Miller J, Reilly P, Witztum J. Apolipoprotein C-II and C-III levels in hyperlipoproteinemia. Metabolism 1979;28:1001-1010.
74. Curry MD, McConathy WJ, Fesmire JD, Alaupovic P. Quantitative determination of human apolipoprotein C-III by electroimmunoassay. Biochim Biophys Acta 1980;617:505-513.
75. Kashyap ML, Srivastava LS, Hynd BA, Gartside PS, Perisutti G. Quantitation of human apolipoprotein C-III and its subspecies by radioimmunoassay and analytical isoelectric focusing: abnormal plasma triglyceride-rich lipoprotein apolipoprotein C-III subspecie concentrations in hypertriglyceridemia. J Lipid Res 1981;22:800-810.
76. Barr SI, Kottke BA, Mao SJT. Postprandial exchange of apolipoprotein C-III between plasma lipoproteins. Am J Clin Nutr 1981;34:191-198.
77. Carlson LA, Holmquist L. Concentrations of apolipoproteins B, C-I, C-II, C-III and E in sera from normal men and their relation to serum lipoprotein levels. Clin Chim Acta 1982;124:163-178.
78. Gustafson S, Östlund-Lindqvist A-M, Vessby B. A rapid radioimmuno assay of human apolipoproteins C-II and C-III. Scand J Clin Lab Invest 1984;44:291-297.
79. Bury J, De Keersgieter W, Rosseneu M, Belpaire F, Christophe J. Immunonephelometric quantitation of the apolipoprotein C-III in human plasma. Clin Chim Acta 1985;145:249-258.
80. Bury J, Rosseneu M. Enzyme linked immunosorbent assay for human apolipoprotein C-III. J Clin Chem Clin Biochem 1985;23:63-68.
81. Parsy D, Clavey V, Fievet C, Kora I, Duriez P, Fruchart JC. Quantification of apolipoprotein C-III in serum by a noncompetitive immunoenzymometric assay. Clin Chem 1985;31:1632-1635.
82. Itakura K, Matsudate T, Sakurai T, Hashimoto S, Ito K, Kanno H, Hirata M, Nakamura K. Single radial immunodiffusion of serum apolipoproteins C-II, C-III and E - pretreatment of samples with surfactant. Clin Chim Acta 1986;161:275-282.
83. Fu M, Liu B, Liu W, Fang D. Competitive enzyme immunoassay for human serum apolipoprotein CI, CII and CIII. Clin Chim Acta 1987;167:339-340.
84. Attman P-O, Alaupovic P. Lipid and apolipoprotein profiles of uremic dyslipoproteinemia - relation to renal function and dialysis. Nephron 1991;57: 401-410.
85. Bren ND, Rastogi A, Kottke BA. Quantification of human plasma apolipoproteins C-I, C-II, and C-III by radioimmunoassays. Mayo Clin Proc 1993; 68:657-664.
86. Bijvoet S, Gagné C, Henderson HE, Fruchart J-C, Dallongeville J, Alaupovic P, Prins M, Kastelein JJP, Hayden MR. Alterations in plasma lipoproteins and apolipoproteins before the age of 40 in the heterozygotes for lipoprotein lipase deficiency. J Lipid Res 1996;37:640-650.
87. Fredenrich A, Giroux L-M, Tremblay M, Krimbou L, Davignon J, Cohn JS. Plasma lipoprotein distribution of apoC-III in normolipidemic and hypertriglyceridemic subjects: comparison of the apoC-III in apoE ratio in different lipoprotein fractions. J Lipid Res 1997;38:1421-1432.
88. Kottke BA, Moll PP, Michels VV, Weidman WH. Levels of lipids, lipoproteins, and apolipoproteins in a defined population. Mayo Clin Proc 1991;66: 1198-1208.
89. Yano T, Nakamura N, Uzawa H, Kobori S, Maruyama H, Takeda H, Kiyota S, Fukushima H, Ichinose K, Migiyama T, Iseki T, Wakamatsu T, Shimada M. Multiple regression analysis of sixteen risk factors including serum apolipoproteins in angiographically documented coronary artery disease. Jpn Circ J 1987;51:383-394.
90. Alaupovic P, Mack WJ, Knight-Gibson C, Hodis HN. The role of triglyceride-rich lipoprotein families in the progression of atherosclerotic lesions as determined by sequential coronary angiography from a controlled clinical trial. Arterioscler Thromb Vasc Biol 1997;17:715-722.
91. Curry MD, McConathy WJ, Alaupovic P, Ledford JD, Popovic M. Determination of human apo lipoprotein E by electroimmunoassay. Biochim Biophys Acta 1976;439:413-425.
92. Blum CB, Aron L, Sciacca R. Radioimmunoassay studies of human apolipoprotein E. J Clin Invest 1980;66:1240-1250.
93. Havel RJ, Kotite L, Vigne J-L, Kane JP, Tun P, Phillips N, Chen GC. Radioimmunoassay of human arginine-rich apolipoprotein, apoprotein E. J Clin Invest 1980;66:1351-1362.
94. Mackie A, Caslake MJ, Packard CJ, Shepherd J. Concentration and distribution of human plasma apolipoprotein E. Clin Chim Acta 1981;116:35-45.
95. Suarez BK, Schonfeld G. Characterization of apolipoprotein E (apoE) apoprotein levels in the various apoE phenotypes. J Clin Endocrinol Metab 1981; 53:435-438.
96. Denisenko AD, Usatenko MS, Losovsky V T, Tryufanov VF, Oleynik IA, Magracheva EY, Klimov AN. Apolipoproteins A-I, A-II and E as well as high density lipoproteins in blood of persons with disalphalipoproteinemias. Vopr Med Khim 1980;27:272-280.
97. Yamada N, Murase T, Akanuma Y, Itakura H, Kosaka K. Plasma apolipoprotein E levels in hypertriglyceridemia. Horm Metab Res 1982;14:303-306.
98. Avogaro P, Bittolo Bon G, Cazzolato G, Pontoglio E, Kostner GM. Distribution and concentration of apolipoprotein E in high and low density lipoproteins. La Ricerca Clin Lab 1983;13:431-436.
99. Weisweiler P, Schwandt P. Immunonephelometric quantitation of apolipoprotein in human serum. J Clin Chem Clin Biochem 1983;21:227-230.
100. Weisweiler P, Janetschek P, Schwandt P. Influence of polyunsaturated fats and fat restriction on serum lipoproteins in humans. Metabolism 1985;34:83-87.
101. Bury J, Vercaemst R, Rosseneu M, Belpaire F. Apolipoprotein E quantified by enzyme-linked immunosorbent assay. Clin Chem 1986;32:265-270.
102. Koffigan M, Kora I, Clavey V, Bard J-M, Chapman J, Fruchart J-C. Quantification of human apolipoprotein E in plasma and lipoprotein subfractions by a non-competitive enzyme immunoassay. Clin Chim Acta 1987;163: 245-256.
103. Rifai N, Silverman LM. A simple immunotechnique for the determination of serum concentration of apolipoprotein E. Clin Chim Acta 1987;163: 207-213.
104. Leroy A, Vu-Dac N, Koffigan M, Clavey V, Fruchart JC. Characterization of a monoclonal antibody that binds to apolipoprotein E and to lipoprotein of human plasma containing apo E. Applications to Elisa quantification of plasma apo E. J Immunoassay 1988;9:309-334.
105. Attman P-O, Alaupovic P, Tavella M, Knight-Gibson C. Abnormal lipid and apolipoprotein composition of major lipoprotein density classes in patients with chronic renal failure. Nephrol Dial Transplant 1996; 1163-1169.
106. Miller NE, Hammett F, Saltissi S, Rao S, VanZeller H, Coltart J, Lewis B. Relation of angiographically defined coronary artery disease to plasma lipoprotein subfractions and apolipoproteins. BMJ 1981;282:1741-1744.
107. Marcovina SM, Albers JJ, Dati F, Ledue TB, Ritchie RF. International Federation of Clinical Chemistry Standardization Project for measurements of apolipoproteins A-I and B. Clin Chem 1991;37:1676-1682.
108. Albers JJ, Marcovina SM, Kennedy H. International Federation of Clinical Chemistry Standardization Project for measurements of apo lipoproteins-A-I and apolipoproteins-B. II. Evaluation and selection of candidate reference materials. Clin Chem 1992;38:658-662.
109. Marcovina SM, Albers JJ, Henderson LO, Hannon WH. International Federation of Clinical Chemistry Standardization Project for measurements of apolipoproteins A-I and B. III. Comparability of apolipoprotein A-I values by use of international reference material. Clin Chem 1993;39:773-781.
110. Marcovina SM, Albers JJ, Kennedy H, Mei JV, Henderson LO, Hannon WH. International Federation of Clinical Chemistry Standardization Project for measurements of apolipoproteins A-I and B. IV. Comparability of apolipoprotein B values by use of International Reference Material. Clin Chem 1994;40:586-592.
111. Bachorik PS, Lovejoy KL, Carroll MD, Johnson CL, Albers JJ, Marcovina SM. Measurement of apolipoproteins A-I and B during the National Health and Nutrition Examination Survey (NHANES) III. Clin Chem 1994; 40:1915-1920.
112. Contois JH, McNamara JR, Lammi-Keefe CJ, Wilson PWF, Massov T, Schaefer EJ. Reference intervals for plasma apolipoprotein A-I determined with a standardized commercial immunoturbidimetric assay: results from the Framingham Offspring Study. Clin Chem 1996;42:507-514.
113. Contois JH, McNamara JR, Lammi-Keefe CJ, Wilson PWF, Massov T, Schaefer EJ. Reference intervals for plasma apolipoprotein B determined with a standardized commercial immunoturbidimetric assay: results from the Framingham Offspring Study. Clin Chem 1996;42:515-523.